1) Strategic Transformation and Leadership Vision
- EssilorLuxottica is undergoing a significant transformation from a traditional optical company to a med-tech and data-driven group, aiming to shape the future of health and human performance.
- The company recorded a revenue growth of 18% in Q4 2025 and 11% for the full year, marking a historic double-digit growth.
- The introduction of AI glasses has been pivotal, with over 7 million units sold in 2025, driven by strong brand performance from Ray-Ban and Oakley.
- The leadership emphasizes the importance of integrating AI glasses into a broader med-tech vision, expanding into areas such as predictive medicine and early detection of health conditions.
2) Financial Performance and Segment Results
- Full-year revenue reached EUR 28.5 billion, with adjusted operating profit at EUR 4.5 billion, despite a EUR 300 million headwind from U.S. tariffs and adverse exchange rates.
- Q4 performance highlighted a 24% growth in North America, 16% in EMEA, and 12% in Asia Pacific, with Latin America showing an 8% increase.
- The company achieved a record free cash flow of EUR 2.8 billion, up EUR 400 million from the previous year.
| Metric |
Q4 2025 Growth |
Full Year 2025 Growth |
| Revenue (constant currency) |
18% |
11% |
| Operating Profit |
- |
EUR 4.5 billion |
| Free Cash Flow |
EUR 2.8 billion |
- |
3) Challenges and Headwinds
- The company faced challenges from U.S. tariffs, which impacted gross margins, alongside adverse foreign exchange rates.
- The gross margin decreased by 260 basis points year-over-year, attributed mainly to tariffs and the higher contribution of AI glasses to revenue.
- Ongoing foreign exchange headwinds are expected to persist into 2026, with a projected impact of about 6 percentage points on results.
4) Operational and Product Plans
- EssilorLuxottica plans to expand its capabilities in AI glasses, with a focus on increasing production capacity in partnership with Meta.
- The myopia management portfolio grew by 22% in 2025, with Stellest lenses gaining traction, particularly in the U.S. market, where reimbursement coverage is improving.
- The company is committed to enhancing its logistics and distribution networks, leveraging both physical retail and e-commerce to drive growth.
5) Guidance and Outlook
- The company is optimistic about its long-term outlook, expecting aligned growth of revenues and operating profits over the next five years.
- There is a focus on expanding the AI glasses portfolio and enhancing the Stellest product line in the U.S. market.
- The transcript lacks specific guidance figures for 2026, particularly regarding expected margin impacts and detailed projections for wearables.
Bottom line: EssilorLuxottica is poised for continued growth driven by its strategic transformation into a med-tech leader, bolstered by strong financial performance and innovative product offerings, despite facing headwinds from tariffs and foreign exchange fluctuations. Shareholders can expect a promising trajectory as the company expands its market presence and product capabilities.
